Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Första AP-fonden (AP1) is one of the five buffer funds within the Swedish national pension system, tasked with managing capital to promote the long-term stability of the retirement scheme. While not a life sciences company itself, AP1 is a major institutional investor that provides significant capital to the global healthcare, biotechnology, and pharmaceutical sectors through its diversified equity portfolio. The fund operates with a mandate for sustainable investment, integrating environmental, social, and governance (ESG) factors into its decision-making processes. AP1 invests across various asset classes, including listed equities, fixed income, real estate, and alternative investments, maintaining a global reach that includes many of the world's leading healthcare innovators.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Första AP-fonden.